See today's report in the Lancet on "How Vioxx is changing US drug regulation".
at the core of the statement is "Vioxx's fallout goes well beyond Merck and its ledgers. Manufacturers facing mounting political pressure have now agreed to scale back advertising—an activity once staunchly defended by the industry. Meanwhile, the US Food and Drug Administration (FDA) has taken what some see as a defensive posture designed to avoid another safety debacle."
Maybe it is time for public health and clinical medicine to band together to push for a total ban on prescription drug advertising.
Leave a comment